fr en

Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.

Caffeic acid phenethyl ester [104594-70-9]

Imprimer

Référence HY-N0274-100mg

Conditionnement : 100mg

Contactez votre distributeur local :

Téléphone : +1 850 650 7790

Marque : MedChemExpress

Demander plus d'informations

Contactez votre distributeur local :

Téléphone : +1 850 650 7790

Description

Caffeic acid phenethyl ester is a NF-κB inhibitor.

IC₅₀ & Target^[1]

NF-κB

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	26.8 μM Compound: 2; CAPE	Cytotoxicity against VHL-deficient human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-deficient human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
786-0	IC₅₀	43.8 μM Compound: 2; CAPE	Cytotoxicity against VHL-positive human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-positive human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
A2780	EC₅₀	3.5 μM Compound: 17; CAPE	Cytotoxicity against human A2780 cells measured after 96 hrs by SRB assay Cytotoxicity against human A2780 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
A549	EC₅₀	27.9 μM Compound: 14	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 12027739]
A549	IC₅₀	10 μM Compound: CAPE	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	[PMID: 28814374]
A549	IC₅₀	26.8 μM Compound: 1, CAPE	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20673727]
A549	IC₅₀	80 μM Compound: 2; CAPE	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33210536]
A549	IC₅₀	83.6 μM Compound: III-19	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 18952420]
A549	IC₅₀	9.72 μM Compound: CAPE	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26638042]
B16-BL6	EC₅₀	6.79 μM Compound: 14	Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 12027739]
B16-F10	IC₅₀	10.68 μM Compound: CAPE	Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 26638042]
Bel-7402	IC₅₀	5.5 μM Compound: III-19	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 18952420]
BEL-7404 tumor cell line	IC₅₀	14.5 μM Compound: 1, CAPE	Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay	[PMID: 20673727]
BeWo	IC₅₀	2.96 μM Compound: I-18	Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
BGC-823	IC₅₀	19.3 μM Compound: 1, CAPE	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 20673727]
BV-2	IC₅₀	6.4 μM Compound: 1, CAPE	Antineuroinflammatory activity in mouse BV2 cells assessed as reduction of LPS-induced nitric oxide production treated 3 hrs before LPS addition measured after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as reduction of LPS-induced nitric oxide production treated 3 hrs before LPS addition measured after 24 hrs by Griess assay	[PMID: 23726032]
BV-2	IC₅₀	6.4 μM Compound: 1, CAPE	Inhibition of nitric oxide production in LPS-stimulated mouse BV2 cells treated 3 hrs before LPS addition measured after 24 hrs by Griess assay Inhibition of nitric oxide production in LPS-stimulated mouse BV2 cells treated 3 hrs before LPS addition measured after 24 hrs by Griess assay	[PMID: 23870700]
BV-2	IC₅₀	6.4 μM Compound: 1, CAPE	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS challenge measured after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS challenge measured after 24 hrs by Griess assay	[PMID: 24697335]
Caco-2	IC₅₀	11.35 μM Compound: CAPE	Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 26638042]
CNE	IC₅₀	54 μM Compound: 1, CAPE	Cytotoxicity against human CNE cells after 72 hrs by MTT assay Cytotoxicity against human CNE cells after 72 hrs by MTT assay	[PMID: 20673727]
DU-145	IC₅₀	16 μM Compound: CAPE	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 27979593]
ECa-109 cell line	IC₅₀	42.6 μM Compound: 1, CAPE	Cytotoxicity against human ECA109 cells after 72 hrs by MTT assay Cytotoxicity against human ECA109 cells after 72 hrs by MTT assay	[PMID: 20673727]
ECa-109 cell line	IC₅₀	47.5 μM Compound: CAPE	Antiproliferative activity against human ECA109 cells after 48 hrs by MTT assay Antiproliferative activity against human ECA109 cells after 48 hrs by MTT assay	[PMID: 27979593]
FaDu	EC₅₀	12.1 μM Compound: 17; CAPE	Cytotoxicity against human FADU cells measured after 96 hrs by SRB assay Cytotoxicity against human FADU cells measured after 96 hrs by SRB assay	[PMID: 31158743]
HeLa	EC₅₀	2.36 μM Compound: 14	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 12027739]
HeLa	IC₅₀	0.068 μg/mL Compound: 9	Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA	[PMID: 19942440]
HeLa	IC₅₀	33 μM Compound: CAPE	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27979593]
HeLa	IC₅₀	37.98 μM Compound: I-18	Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HeLa	IC₅₀	8.8 μM Compound: 1, CAPE	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20673727]
HepG2	IC₅₀	40.87 μM Compound: I-18	Antitumor activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HL-60	IC₅₀	16.65 μM Compound: I-18	Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HL-60	IC₅₀	9.8 μM Compound: 1, CAPE	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20673727]
HT-1080	EC₅₀	9.5 μM Compound: 14	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 12027739]
HT-29	EC₅₀	>30 μM Compound: 17; CAPE	Cytotoxicity against human HT-29 cells measured after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
HUVEC	EC₅₀	8 μM Compound: CAPE	Cytoprotective activity against H2O2-induced oxidative stress in HUVEC cells after 18 hrs by Cell-Titer Blue assay Cytoprotective activity against H2O2-induced oxidative stress in HUVEC cells after 18 hrs by Cell-Titer Blue assay	[PMID: 20598894]
IMR-32	IC₅₀	5 μM Compound: 2; CAPE	Cytotoxicity against human IMR-32 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human IMR-32 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33210536]
J774.1	IC₅₀	4.8 μM Compound: CAPE	Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay	[PMID: 15974608]
JJN-3	IC₅₀	30 μM Compound: 2; CAPE	Growth inhibition of human JJN-3 cells after 48 hrs by PrestoBlue cell viability assay Growth inhibition of human JJN-3 cells after 48 hrs by PrestoBlue cell viability assay	[PMID: 33210536]
K562	IC₅₀	46 μM Compound: 1, CAPE	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 20673727]
KB	IC₅₀	45.2 μM Compound: 1, CAPE	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 20673727]
KMM-1	IC₅₀	37.5 μM Compound: 2; CAPE	Growth inhibition of human KMM-1 cells after 48 hrs by PrestoBlue cell viability assay Growth inhibition of human KMM-1 cells after 48 hrs by PrestoBlue cell viability assay	[PMID: 33210536]
LNCaP	IC₅₀	33.7 μM Compound: 2, CAPE	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay	[PMID: 24080105]
LNCaP	IC₅₀	6.2 μM Compound: 2, CAPE	Antiandrogenic activity in human LNCAP cells assessed as reduction in DHT-stimulated PSA release after 24 hrs by ELISA Antiandrogenic activity in human LNCAP cells assessed as reduction in DHT-stimulated PSA release after 24 hrs by ELISA	[PMID: 24080105]
LS174T	IC₅₀	9.9 μM Compound: 1, CAPE	Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay	[PMID: 20673727]
Macrophage	IC₅₀	15 μM Compound: CAPE	Inhibition of LPS-induced NO production in ddY mouse macrophages after 20 hrs by Griess reagent assay Inhibition of LPS-induced NO production in ddY mouse macrophages after 20 hrs by Griess reagent assay	[PMID: 15270564]
MCF7	EC₅₀	12.1 μM Compound: 17; CAPE	Cytotoxicity against human MCF7 cells measured after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
MCF7	IC₅₀	26.7 μM Compound: III-19	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 18952420]
MCF7	IC₅₀	28.8 μM Compound: CAPE	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27979593]
NIH3T3	EC₅₀	21.4 μM Compound: 17; CAPE	Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
PC-12	IC₅₀	2 μM Compound: CAPE	Neuroprotection activity in rat PC12 cells assessed as reduction in H2O2-induced cell death preincubated for 3 hrs followed by H2O2 addition and measured after 3 hrs by MTS assay Neuroprotection activity in rat PC12 cells assessed as reduction in H2O2-induced cell death preincubated for 3 hrs followed by H2O2 addition and measured after 3 hrs by MTS assay	[PMID: 30928712]
PC-3	IC₅₀	10.15 μM Compound: CAPE	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26638042]
PC-3	IC₅₀	51.4 μM Compound: 2, CAPE	Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue assay Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue assay	[PMID: 24080105]
PC-3	IC₅₀	91 μM Compound: 1, CAPE	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20673727]
Peritoneal macrophage	IC₅₀	4.31 μM Compound: 5; CAPE	Anti-inflammatory activity in ICR mouse peritoneal macrophages assessed inhibition of LPS-induced TNF-alpha production preincubated for 30 to 60 mins followed by LPS stimulation measured after 24 hrs by ELISA Anti-inflammatory activity in ICR mouse peritoneal macrophages assessed inhibition of LPS-induced TNF-alpha production preincubated for 30 to 60 mins followed by LPS stimulation measured after 24 hrs by ELISA	[PMID: 29202400]
Peritoneal macrophage cell	IC₅₀	11 μM Compound: CAPE	Hepatoprotective activity in ddY mouse peritoneal macrophages assessed as inhibition of LPS-induced nitric oxide production after 20 hrs by Griess method relative to untreated control Hepatoprotective activity in ddY mouse peritoneal macrophages assessed as inhibition of LPS-induced nitric oxide production after 20 hrs by Griess method relative to untreated control	[PMID: 19775895]
RAW264.7	EC₅₀	0.193 μM Compound: Table 1, R23C1	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation administered 1 hr before LPS challenge and measured after 24 hrs by Griess reagent assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation administered 1 hr before LPS challenge and measured after 24 hrs by Griess reagent assay	[PMID: 18667320]
RAW264.7	EC₅₀	4.518 μM Compound: Table 1, R23C1	Cytotoxicity against mouse RAW264.7 cells assessed as cell survival after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as cell survival after 24 hrs by MTT assay	[PMID: 18667320]
RAW264.7	IC₅₀	0.39 μM Compound: CAPE	Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS addition and measured after 24 hrs by griess reagent based assay Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS addition and measured after 24 hrs by griess reagent based assay	[PMID: 37976711]
RAW264.7	IC₅₀	3.8 μM Compound: CAPE	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method	[PMID: 22831798]
RAW264.7	IC₅₀	9.3 μM Compound: CAPE	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
RCC4	IC₅₀	14 μM Compound: 2; CAPE	Cytotoxicity against VHL-deficient human RCC4 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-deficient human RCC4 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
RCC4/VHL	IC₅₀	29.1 μM Compound: 2; CAPE	Cytotoxicity against VHL-positive human RCC4/VHL cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-positive human RCC4/VHL cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
SGC-7901	IC₅₀	14.26 μM Compound: I-18	Antitumor activity against human SGC7901 cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human SGC7901 cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
SiHa	IC₅₀	66.92 μM Compound: I-18	Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
SW-1736	EC₅₀	4.7 μM Compound: 17; CAPE	Cytotoxicity against human SW1736 cells measured after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells measured after 96 hrs by SRB assay	[PMID: 31158743]

In Vitro

Caffeic acid phenethyl ester is a NF-κB inhibitor. Cell survival and proliferation of CRPC cell lines are all significantly suppressed by Caffeic acid phenethyl ester (CAPE) treatment dose-dependently. The growth inhibitory effect of Caffeic acid phenethyl ester is evident within 24 hours of treatment but the suppressive effect accumulates over time. The IC₅₀ of 24, 48, 72, and 96 h Caffeic acid phenethyl ester treatment on LNCaP 104-R1 cells is 64.0, 30.5, 20.5, and 18.0 μM, respectively. Colony formation assay reveals that treatment with 10 μM Caffeic acid phenethyl ester reduces colony formation of LNCaP 104-R1 cells by 90% while treatment with 20 μM Caffeic acid phenethyl ester completely blocks the formation of LNCaP 104-R1 colonies. Flow cytometric analysis reveals a reduction of cells in the S phase and G2/M phase but an increase of cells in the G1 phase population in LNCaP 104-R1 cells under Caffeic acid phenethyl ester treatment. Caffeic acid phenethyl ester treatment also significantly decreases protein levels of fatty acid synthase (FAS), retinoblastoma protein (Rb), phospho-Rb Ser807/811, c-Myc, p70S6kinase, phospho-p70S6kinase Thr421/Ser424, Skp2, p90RSK, and NF-κB p65^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (351.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5173 mL	17.5864 mL	35.1729 mL
5 mM	0.7035 mL	3.5173 mL	7.0346 mL
10 mM	0.3517 mL	1.7586 mL	3.5173 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 20 mg/mL (70.35 mM); Clear solution; Need ultrasonic

Pureté et documentation

Purity: 99.85%

Fiche technique (277 KB) SDS (396 KB)

COA (244 KB) LCMS (98 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Lin HP, et al. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget. 2015 Mar 30;6(9):6684-707. [Content Brief]

Vous serez peut-être également intéressé par les produits suivants :

Référence

Description

Cond.

Prix HT

HY-B0275-50mg

Oxytetracycline [79-57-2]

50mg

HY-B2122-500mg

Maltitol [585-88-6]

500mg

HY-B0275A-100mg

Oxytetracycline (hydrochloride) [2058-46-0]

100mg

Caffeic acid phenethyl ester [104594-70-9]

Référence HY-N0274-100mg

Contactez votre distributeur local :

Marque : MedChemExpress

Contactez votre distributeur local :

Caffeic acid phenethyl ester Related Antibodies

Vous serez peut-être également intéressé par les produits suivants :